Whole blood transfusion in adult patients with traumatic brain injury: A systematic review and meta-analysis
In brief
Whole blood has not been shown to lower mortality after traumatic brain injury
In a review of five studies, pooled results from four did not establish a mortality benefit from whole blood transfusion for adults with traumatic brain injury. The estimated death rate was 15% lower, but results were imprecise and evidence certainty was very low; randomized trials are needed to determine whether whole blood improves survival.
- Journal
- The American journal of emergency medicine (Q1)
- Published
- 5 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Tatsunori Nagamura, Hiroaki Taniguchi, Shu Utsumi, Kohei Yamada, Takero Terayama, Kaushik Mukherjee, et al.
- PMID
- 43025005
- DOI
- 10.1016/j.ajem.2026.10.039
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (top studies of the week, 15 November 2026): Compares transfusion strategies and mortality after traumatic brain injury
- Picked for Emergency Medicine (top studies of the week, 15 November 2026): Transfusion strategy evidence for traumatic brain injury resuscitation
Abstract
BACKGROUND: Whole blood (WB) transfusion may improve outcomes in trauma patients compared with component therapy, but evidence in traumatic brain injury (TBI) remains limited. We evaluated the clinical effectiveness of WB transfusion in adults with TBI requiring transfusion. METHODS: We searched PubMed, Cochrane CENTRAL, CINAHL, ClinicalTrials.gov, and ICTRP for studies published from January 2006 through August 31, 2026. Eligible studies included randomized trials and observational studies using propensity score matching or inverse probability of treatment weighting. Random-effects meta-analysis with Hartung-Knapp adjustment was performed for mortality. Component-specific transfusion requirements were summarized qualitatively. RESULTS: Five studies were included in the systematic review, and four studies were included in the mortality meta-analysis. WB transfusion was not clearly associated with lower mortality (RR, 0.85; 95% CI, 0.62-1.16; P = 0.19; I2 = 48.3%), with a 95% prediction interval of 0.48-1.49. Sensitivity analyses using alternative effect-size conversion methods, baseline risks, effect measures, and mortality definitions yielded consistent results. In exploratory leave-one-out analyses, pooled RRs ranged from 0.74 to 0.91, with all 95% CIs including 1. Three studies contributed component-specific transfusion data; red blood cells and plasma requirements were generally lower with WB, although this may partly reflect substitution by WB itself. The certainty of evidence was very low. CONCLUSIONS: Current evidence is insufficient to determine whether WB transfusion reduces mortality after TBI because of the limited number of studies, clinical and methodological heterogeneity, risk of bias, and imprecision. Further randomized trials in clearly defined TBI populations are needed.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.